DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Ajanta Pharma Limited — Outcome of Board Meeting

NSE 1 hr ago·30 Jul 2026, 9:05 am

Ajanta Pharma

Ajanta Pharma has informed the stock exchanges that its board has approved the financial results for the period ending June 30, 2026. This regulatory filing confirms that the company has completed the internal review and reporting process for this quarter.

For investors, this update is a routine but important milestone. It provides the first official confirmation of the company's performance during this specific period, allowing the market to assess the firm's operational health and financial trajectory ahead of any detailed disclosures.

Investors should now watch for the detailed press release and the audited financial statements. These documents will provide the specific numbers regarding revenue, profit, and operational expenses, which are essential for a deeper analysis of the company's current standing.